share_log

424B3: Prospectus

424B3: Prospectus

424B3：募资说明书
美股SEC公告 ·  12/16 15:03

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. has issued a $5,737,500 convertible promissory note to A.G.P./Alliance Global Partners, due November 25, 2025. The note accrues 5.5% annual interest and is convertible to common stock at $0.10 per share, subject to adjustments and stockholder approval. Concurrently, Conduit amended its existing $2.65 million note with Nirland Limited, allowing conversion at the same rate.Both notes require stockholder approval for conversion and could potentially result in the issuance of up to 133 million new common shares combined. The company must file a resale registration statement for the new note within specified timeframes. If stockholder approval for the Nirland note conversion is not obtained by January 9, 2025, Conduit faces a $100,000 per day penalty.The notes are unsecured, governed by New York law, and were issued under exemptions from SEC registration requirements. Conduit may suspend the use of the prospectus for up to 60 total trading days in a 12-month period if needed to amend the registration statement.
Conduit Pharmaceuticals Inc. has issued a $5,737,500 convertible promissory note to A.G.P./Alliance Global Partners, due November 25, 2025. The note accrues 5.5% annual interest and is convertible to common stock at $0.10 per share, subject to adjustments and stockholder approval. Concurrently, Conduit amended its existing $2.65 million note with Nirland Limited, allowing conversion at the same rate.Both notes require stockholder approval for conversion and could potentially result in the issuance of up to 133 million new common shares combined. The company must file a resale registration statement for the new note within specified timeframes. If stockholder approval for the Nirland note conversion is not obtained by January 9, 2025, Conduit faces a $100,000 per day penalty.The notes are unsecured, governed by New York law, and were issued under exemptions from SEC registration requirements. Conduit may suspend the use of the prospectus for up to 60 total trading days in a 12-month period if needed to amend the registration statement.
Conduit Pharmaceuticals Inc. 向 A.G.P./Alliance Global Partners 发行了一张 5,737,500 美元的可转换票据，到期日为 2025 年 11 月 25 日。该票据按年利率 5.5% 计息，并可按每股 0.10 美元的价格转换为普通股，具体调整及需经股东批准。与此同时，Conduit 修改了与 Nirland Limited 现有的 265万美元票据，使其允许以相同的汇率进行转换。这两张票据均需股东批准方可转换，并可能导致最多 13300万新普通股的发行。公司必须在规定的时间内为新的票据提交转售注册声明。如果在 2025 年 1 月...展开全部
Conduit Pharmaceuticals Inc. 向 A.G.P./Alliance Global Partners 发行了一张 5,737,500 美元的可转换票据，到期日为 2025 年 11 月 25 日。该票据按年利率 5.5% 计息，并可按每股 0.10 美元的价格转换为普通股，具体调整及需经股东批准。与此同时，Conduit 修改了与 Nirland Limited 现有的 265万美元票据，使其允许以相同的汇率进行转换。这两张票据均需股东批准方可转换，并可能导致最多 13300万新普通股的发行。公司必须在规定的时间内为新的票据提交转售注册声明。如果在 2025 年 1 月 9 日之前未获得 Nirland 票据转换的股东批准，Conduit 将面临每天 100,000 美元的罚款。这些票据是无担保的，受纽约法律管辖，并根据 SEC 注册要求的豁免发行。若需要修改注册声明，Conduit 可暂停使用招股说明书，累计最多 60 个交易日，限于 12 个月内。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间